Inotrem: Clinical Trials

7 trials sponsored by Inotrem, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 active not recruiting, 1 recruiting, 1 unknown. 3 Phase 2, 1 Not applicable, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Completed 2, Active not recruiting 1
Not applicable1Unknown 1
Phase 11Completed 1

Follow Inotrem: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of an Anti-TREM-1 Treatment on an ex Vivo Human Intestinal Model
Additional biopsies and blood samples - Inflammatory Bowel Diseases
RecruitingInotrem402023-01-312025-02-27
Pilot Study of the Predictive Value of TREM1 Expression and Activation in Inflammation and Radio-induced Mammary Fibrosis
Blood sampling - Radiation Toxicity, Fibrosis
Not applicableUnknownCentre Francois Baclesse, Luxembourg202022-04-012022-06-23
TREM-1 Pathway Activation in COVID-19
blood sampling - Covid19
CompletedCentral Hospital, Nancy, France8302020-10-012022-03-22
Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support
nangibotide, placebo - COVID19
Phase 2CompletedInotrem2202020-09-232023-05-03
Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock
nangibotide low dose, nangibotide high dose, placebo - Shock, Septic
Phase 2Active not recruitingInotrem3552019-11-132023-04-11
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock
Nangibotide 0.3 mg/kg, Placebo, Nangibotide 1 mg/kg - Shock, Septic
Phase 2CompletedInotrem502017-07-032024-10-08
Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects
nangibotide, Placebo - Healthy Subjects
Phase 1CompletedInotrem272016-04-012025-02-10

Conditions studied

COVID-19 (2)  ·  Shock, Septic (2)  ·  Breast Neoplasms (1)  ·  Fibrosis (1)  ·  Inflammatory Bowel Diseases (1)  ·  Radiation Injuries (1)  ·  Sepsis (1)

Interventions

nangibotide (4)  ·  Blood Specimen Collection (3)

Countries

France (5)  ·  Belgium (3)  ·  Spain (2)  ·  Denmark (1)  ·  Finland (1)  ·  Ireland (1)  ·  Italy (1)  ·  Luxembourg (1)  ·  Netherlands (1)  ·  United Kingdom (1)

Top investigators

Jean-Jacques Garaud, MD (2)

Results publications

PMID 29885068, PMID 34233965, PMID 37269870, PMID 37350989

NIH funding

2018 (1)